By far, the biggest new position picked up by institutions has been AbbVie (ABBV - Get Report). That's not surprising; after all, the $67 billion pharma firm only spun off from Abbott Labs (ABT) early this year. Between new purchases and distributions for firms that already owned ABT, funds added 97.2 million shares of ABBV to their portfolios in the first quarter. That's a $4 billion position at current price levels.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts